

FOR VETERINARY USE ONLY

# Resbovis MAX

BOVINE COMBINED INACTIVATED VACCINE



## Dollvet

### SUSPENSION FOR INJECTION

#### COMPOSITION:

The content of each dose of vaccine (5 ml) is as follows:

| Active ingredient                                             | Quantity                     |
|---------------------------------------------------------------|------------------------------|
| Inactivated Bovine herpesvirus Type-1 (BoHV-1) antigen        | ≥ 4 log <sub>2</sub> VNT*    |
| Inactivated Bovine respiratory syncytial virus (BRSV) antigen | ≥ 4 log <sub>2</sub> VNT*    |
| Inactivated Bovine parainfluenza virus-3 (BPIV-3) antigen     | ≥ 6 log <sub>2</sub> VNT*    |
| Inactivated Bovine viral diarrhea (CP-BVDV) antigen           | ≥ 6 log <sub>2</sub> VNT*    |
| Inactivated Bovine viral diarrhea (NCP-BVDV) antigen          | ≥ 6 log <sub>2</sub> FAVN**  |
| Inactive Pasteurella multocida antigen                        | ≥ 1/40 ELISA seropositif *** |
| Inactive Mannheimia haemolytica A1 antigen and leukotoxin     | ≥ 1/40 ELISA seropositif *** |
| Excipients                                                    |                              |
| Aluminum hydroxide gel (Al <sup>3+</sup> )                    | 1,5 mg/ml                    |
| Saponin                                                       | 0,3 mg/ml                    |
| Formaldehyde solution (37%)                                   | 0,004 ml/ml                  |

\*VNT (log<sub>2</sub>) titer in rabbits vaccinated with 1/2 dose

\*\*Titer of FAVN (log<sub>2</sub>) in rabbits vaccinated with 1/2 dose

\*\*\*ELISA titer in rabbits vaccinated with 1/2 dose

#### IMMUNOLOGICAL PROPERTIES:

**Pharmacotherapeutic Group:** Immunologically inactive viral and inactivated bacterial vaccines for cattle.

**ATCvet Code:** Q102AL

In cattle, it stimulates the production of antibodies against Infectious Bovine Rhinotracheitis (IBR) virus, Bovine Diarrhea (BVD) virus, Bovine Respiratory Syncytial (BRSV) virus, Bovine Parainfluenza 3 (PI 3) virus, Pasteurella multocida and Mannheimia haemolytica type A1 antigens, reducing infections and lesions caused by these agents.

#### INDICATIONS:

RESBOVIS-MAX is an inactivated vaccine against Infectious Bovine Rhinotracheitis (IBR) virus, Bovine Diarrhea (BVD) virus, Bovine Respiratory Syncytial (BRSV) virus, Bovine Parainfluenza 3 (PI 3) virus, Pasteurella multocida and Mannheimia haemolytica type A1 in cattle. Immunity begins to develop within 3 weeks in vaccinated animals, and immunity occurs by creating a complete immune response 2 weeks after the second vaccination in animals vaccinated for the first time. Active immunity persists for 6 months. The resulting active immunity reduces infections and lesions caused by these factors.

#### METHOD OF ADMINISTRATION AND DOSAGE:

It is administered to **all cattle** from the age of 2 months in the amount of 5 ml subcutaneously (SC) or intramuscularly (IM) to the middle part of the lateral face of the neck or to the immobile area behind the shoulder. Animals vaccinated for the first time are given a second administration after 3 weeks. It is recommended to administer as a single dose every 6 months.

#### CLINICAL PARTICULARS AND SPECIAL WARNINGS FOR TARGET SPECIES:

- Sick and suspicious animals in the incubation period and animals under stress should not be vaccinated.
  - The vaccine should be brought to body temperature before administration.
  - When the vaccine is to be used, the vaccine bottle should be shaken gently before each use.
  - During vaccination, the vaccine bottle should be protected from the sun and kept in ice if possible.
  - Aseptic needles and injectors should be used in each administration.
  - The vaccine should only be administered by a veterinarian or veterinary health technicians under the supervision of a veterinarian.
- Use in pregnancy and lactation:** It is suitable for use during pregnancy and lactation.

#### ADVERSE REACTIONS:

Very common in animals (more than 1 in 10 animals) short-term local reactions (redness, mild swelling and scabs) at the injection site and a transient increase in body temperature may occur. Very rarely (less than 1 in 10,000 animals) susceptible animals may develop an anaphylactic reaction. In this case, symptomatic treatment (antihistamine/antiallergic drugs) can be administered.

# Resbovis MAX

SIĞIR KOMBİNE İNAKTİF AŞI



## Dollvet

### ENJEKSİYONLUK SÜSPANSİYON

#### DRUG INTERACTIONS:

There is no information on the compatibility of this product when used in combination with other vaccines. Therefore, the use of this product on the same day or at different times as other products has not been proven to be safety and efficacy.

#### OVERDOSE, SYMPTOMS IF ANY, EMERGENCY PROCEDURES AND ANTIDOTES:

Since it is an inactivated vaccine, no overdose studies have been conducted.

#### WITHDRAWAL PERIOD:

The withdrawal period for meat, offal, and milk intended for human consumption after vaccination is 0 (zero) days.

#### CONTRAINDICATIONS:

It has no known contraindications.

#### GENERAL WARNINGS:

"Keep out of reach of children."

"Consult your veterinarian before use and in case of an unexpected effect"

#### PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VACCINE AND RECOMMENDATIONS FOR VETERINARIANS:

- There are no known negative effects on human health, but the area should be cleaned and disinfected in case of injuries that may occur during vaccine administration.
- If you accidentally inject yourself with the vaccine, seek medical attention immediately and show your doctor the leaflet or label of the product.

#### STORAGE CONDITIONS AND SHELF LIFE:

**Suspension for injection:** It should be stored at 2-8°C and in the dark. Do not freeze.

Shelf life is 24 months.

Opened bottles should be used within 6-8 hours.

#### DISPOSAL OF WASTE AND RECOMMENDATIONS FOR NON-TARGET SPECIES:

Used or leftover products and waste materials generated by the use of this product must be disposed of in accordance with the relevant legislation. All kinds of waste/residual materials should not be mixed with domestic wastes and wastewater, and should not be disposed of in drainage systems and the environment.

#### PRESENTATION:

The vaccine is packaged in 5 ml Type I amber glass bottles, 25 ml, 50 ml and 100 ml Type II amber glass bottles or 25 ml, 50 ml, 100 ml and 250 ml white polypropylene plastic bottles. Glass and plastic bottles are labelled with a bromobutyl stopper and sealed with an aluminium cap.

5 ml bottles are offered to the market in 10x5 ml plastic tray or cardboard boxes. 25 ml, 50 ml, 100 ml and 250 ml bottles are offered to the market in styrofoam with or without individual boxes. Not all packaging formats may be available to the market at the same time.

LEAFLET APPROVAL DATE: 21.10.2025

DATE OF MARKETING AUTHORIZATION ISSUED BY THE MINISTRY OF AGRICULTURE AND FORESTRY: 21.10.2025

#### NAME AND ADDRESS OF MARKETING AUTHORIZATION HOLDER:

DOLLVET Biyoteknoloji A.Ş.

Konaklar Mahallesi Akasyalı Sokak No:10 Beşiktaş / İstanbul / TÜRKİYE

Telephone: +90 212 422 02 01 Fax: +90 212 422 00 72 E-mail: dollvet@dollvet.com.tr/www.dollvet.com.tr

#### NAME AND ADDRESS OF MANUFACTURER:

DOLLVET Biyoteknoloji A.Ş.

Organize Sanayi Bölgesi Koçören OSB Mah. 106. Cadde, No:6, Eyyübiye/ Şanlıurfa/ TÜRKİYE

Telephone: +90 414 369 11 33 Fax: +90 414 369 16 62 E-mail: dollvet@dollvet.com.tr